To our knowledge, there is currently only one phase 3 trial underway to evaluate anti-PD-L1 therapy in the adjuvant setting of resectable RCC: the “IMmotion010” trial comparing single-agent atezolizumab vs. placebo (ClinicalTrials.gov identifier: NCT03024996). This evidence concerns the gene CD274 and renal cell carcinoma.